| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Teriflunomide |
| Brand | Aubagio® |
| Indication | For the first line treatment of adult patients with relapsing remitting multiple sclerosis (MS). |
| Assessment Process | |
| Rapid review commissioned | 27/08/2013 |
| Rapid review completed | 20/09/2013 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
| Full pharmacoeconomic assessment commissioned by HSE | 25/11/2013 |
| NCPE assessment completed | 19/06/2014 |
| NCPE assessment outcome | Reimbursement Not Recommended. |
The NCPE does not recommend reimbursement of teriflunomide (Aubagio®) at the current price.
The HSE has approved reimbursement following price negotiations-September 2014
